VAERS 2508954
MERCK & CO. INC. · HEP B (RECOMBIVAX HB) · Charge U002527
- Staat
- AL
- Alter
- 44,0
- Geschlecht
- M
- Eingang
- 15.11.2022
- Impfdatum
- 07.09.2022
- Beginn
- 01.09.2022
- Tage bis Beginn
- -
- Dosis
- 2
- Route/Site
- - / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Symptomtext
Received 2nd dose in series as low Hep B antibody levels and employment places higher risk of exposure. Second dose as above with labs through PCP with Transaminitis. Repeat labs 2 weeks later better but still high. Third set of labs through occupational health better / resolving. Two sets of viral tests run including Hep b, Hep c and HIV all negative. Liver US normal. No major medical history otherwise. Felt to be related to Hep B vaccine.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- HIV test negative
- Hospital-Tage
- -
- Labordaten
- Full set of labs including LFTs through PCP, second set of LFTs along with Hep serologies, HIV, celiac antibodies through PCP, liver US. Third set of liver function through occupational health.
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- None
- Andere Medikamente
- None
- Allergien
- Celiac. Gluten. Wheat. Barley. Rye.
- Vorherige Impfungen
- Moderna COVID 1/5/2021